| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Revenue | ||||||
Revenue | ||||||
95,961 | 89,464 | 86,676 | - | - | - | |
Software-as-a-service related | ||||||
- | - | - | 6,750 | 14,292 | 8,372 | |
Software and hardware related | ||||||
- | - | - | 56,210 | 13,926 | 9,778 | |
Maintenance | ||||||
- | - | - | 9,089 | 9,199 | 5,345 | |
Total software-related revenue | ||||||
- | - | - | 62,960 | 28,218 | 18,150 | |
Sequencing and molecular analysis | ||||||
- | - | - | 604 | 75 | 0 | |
Home health care services | ||||||
- | - | - | 7,751 | 8,685 | 10,426 | |
Total net revenue | ||||||
- | - | - | 80,404 | 46,177 | 33,921 | |
Cost of Revenue: | ||||||
Total cost of revenue | ||||||
38,422 | 44,269 | 41,522 | - | - | - | |
Software-as-a-service related | ||||||
- | - | - | 19,883 | 3,227 | 8,026 | |
Software and hardware related | ||||||
- | - | - | 816 | -153 | 1,025 | |
Maintenance | ||||||
- | - | - | 798 | 411 | 438 | |
Amortization of developed technologies | ||||||
- | - | - | 8,492 | 5,901 | 7,694 | |
Total software-related cost of revenue | ||||||
- | - | - | 20,699 | 3,074 | 9,051 | |
Sequencing and molecular analysis | ||||||
- | - | - | 1,987 | 39 | 0 | |
Home health care services | ||||||
- | - | - | 12,131 | 11,263 | 7,047 | |
Cost of Revenue | ||||||
- | - | - | 44,107 | 20,688 | 24,230 | |
Gross Profit | ||||||
57,539 | 45,195 | 45,154 | 36,297 | 25,489 | 9,691 | |
Operating Expenses | ||||||
Selling, general and administrative | ||||||
61,043 | 70,763 | 74,976 | 105,258 | 55,717 | 46,209 | |
Research and development | ||||||
19,072 | 20,916 | 33,862 | 47,310 | 14,248 | 16,979 | |
Amortization of acquisition-related assets | ||||||
4,217 | 4,217 | 4,216 | 4,217 | 22 | 7,033 | |
Impairment of intangible asset | ||||||
3,977 | 0 | - | - | - | 24,150 | |
Total operating expenses | ||||||
88,309 | 95,896 | 113,054 | 156,785 | 69,987 | 94,371 | |
Loss from operations | ||||||
-30,770 | -50,701 | -67,900 | -120,488 | -44,498 | -84,680 | |
Interest expense, net | ||||||
-18,044 | -17,120 | -16,168 | -6,429 | -627 | -980 | |
Other income (expense), net | ||||||
-5,625 | -17,876 | 800 | 3,593 | 2,410 | -477 | |
Income (Loss) from Equity Method Investments | ||||||
-8,317 | -108,409 | -50,334 | -40,994 | -2,584 | 1,525 | |
Loss from continuing operations before income taxes | ||||||
-62,756 | -194,106 | -133,602 | -164,318 | -45,299 | -84,612 | |
Provision for income taxes | ||||||
-112 | -3,673 | -2,203 | -23,797 | 391 | 5 | |
Net loss from continuing operations | ||||||
-62,644 | -190,433 | -131,399 | -140,521 | -45,690 | - | |
Income (loss) from discontinued operations, net of tax | ||||||
-118 | -1,719 | -43,812 | -43,581 | -26,321 | - | |
Net loss | ||||||
- | - | - | - | - | -84,617 | |
Less: Net loss attributed to non-controlling interests | ||||||
- | - | - | - | - | -192 | |
Net Income (Loss) Attributable to Parent | ||||||
-62,762 | -192,152 | -175,211 | -184,102 | -72,011 | -84,425 | |
Basic and diluted net income (loss) per share | ||||||
Continuing operations - common stock (in usd per share) | ||||||
-0.57 | -1.74 | - | - | - | - | |
Discontinued operations - common stock (in usd per share) | ||||||
0.00 | -0.02 | - | - | - | - | |
Total net income (loss) per share - common stock (in usd per share) | ||||||
-0.57 | -1.76 | - | - | - | - | |
Weighted average shares outstanding | ||||||
Basic - common stock | ||||||
110,351 | 109,168 | - | - | - | - | |
Diluted - common stock | ||||||
110,468 | 109,168 | - | - | - | - | |
Software-as-a-service related | ||||||
Net revenue | ||||||
72,831 | 65,646 | 60,730 | - | - | - | |
Total cost of revenue | ||||||
23,233 | 23,691 | 21,939 | - | - | - | |
Software and hardware related | ||||||
Net revenue | ||||||
8,015 | 4,534 | 7,648 | - | - | - | |
Total cost of revenue | ||||||
2,886 | 3,335 | 4,749 | - | - | - | |
Maintenance | ||||||
Net revenue | ||||||
10,519 | 9,834 | 10,421 | - | - | - | |
Total cost of revenue | ||||||
1,625 | 924 | 749 | - | - | - | |
Total software-related revenue | ||||||
Revenue | ||||||
91,365 | 80,014 | 78,799 | - | - | - | |
Total cost of revenue | ||||||
32,406 | 32,883 | 32,609 | - | - | - | |
Sequencing and molecular analysis | ||||||
Revenue | ||||||
1,733 | 3,129 | 2,554 | - | - | - | |
Total cost of revenue | ||||||
4,545 | 8,055 | 6,084 | - | - | - | |
Home Health Care Services [Member] | ||||||
Revenue | ||||||
2,863 | 6,321 | 5,323 | - | - | - | |
Total cost of revenue | ||||||
1,471 | 3,331 | 2,829 | - | - | - | |
Amortization of developed technologies | ||||||
Total cost of revenue | ||||||
4,662 | 4,933 | 5,172 | - | - | - | |
Common Stock | ||||||
Continued operations - common stock (usd per share) | ||||||
- | - | -1.12 | - | - | - | |
Discontinued operations - common stock (usd per share) | ||||||
- | - | -0.37 | - | - | - | |
Total net loss per common stock (usd per share) | ||||||
- | - | -1.49 | - | - | - | |
Basic and diluted (shares) | ||||||
- | - | 116,737 | - | - | - | |